Helen Neville-Webbe - Concepedia

Author

Helen Neville-Webbe

Also Known As

H L Neville-Webbe, H Neville-Webbe, H. L. Neville‐Webbe, H.L Neville-Webbe, H.L. Neville-Webbe, Helen L Neville-Webbe, Helen L. Neville-Webbe, Helen L. Neville‐Webbe, Helen Neville-Webbe

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

University of Sheffield Weston Park Cancer Centre University of Leeds Royal Hallamshire Hospital Cambridge University Hospitals NHS Foundation Trust

About

Helen Neville-Webbe is an author at University of Sheffield specializing in medicine, cancer research, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	480
2	Cell Biology	4	4	409
3	Pathology	2	2	228
4	Pharmacology	2	2	113
5	Immunology	1	1	139

Helen Neville-Webbe

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial Helena Earl, Louise Hiller, Anne-Laure Vallier, The Lancet	2019	277
Sequence‐ and schedule‐dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells Helen Neville-Webbe, Amin Rostami‐Hodjegan, Catherine A. Evans, International Journal of Cancer	2004	147
Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis Helen Neville-Webbe, Neil A. Cross, Colby L. Eaton, Breast Cancer Research and Treatment SclerostinBone Morphogenic ProteinApoptosisImmunologyCell Death	2004	139
Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival? Ingunn Holen, Simon S. Cross, Helen Neville-Webbe, Breast Cancer Research and Treatment Tumor BiologyBreast OncologyBreast Cancer CellsCancer Cell BiologyPathology	2005	124
Osteoprotegerin (OPG)—a potential new role in the regulation of endothelialcell phenotype and tumour angiogenesis? Simon S. Cross, Zhiyong Yang, Nicola J. Brown, International Journal of Cancer Endothelial CellsPathologyCell DeathPotential New RoleTumor Biology	2005	104
Mechanisms of the Synergistic Interaction between the Bisphosphonate Zoledronic Acid and the Chemotherapy Agent Paclitaxel in Breast Cancer Cells in vitro Helen Neville-Webbe, Caroline A. Evans, Robert E. Coleman, Tumor Biology	2006	89
Magnesium Depletion in Patients Receiving Cisplatin-based Chemotherapy Elizabeth Hodgkinson, Helen Neville-Webbe, Robert E. Coleman Clinical Oncology Magnesium DepletionOncologyMedicinePharmacotherapyMetronomic Chemotherapy	2006	71
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction Helen Neville-Webbe, Robert E. Coleman, Ingunn Holen British Journal of Cancer	2010	52
Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro Julia K. L. Woodward, Helen Neville-Webbe, Robert E. Coleman, Anti-Cancer Drugs Zoledronic AcidBreast OncologyOncologyMedicineCombined Effects	2005	42
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma Elizabeth Smyth, Samuel Rowley, Fay Cafferty, JAMA Oncology	2019	18

Page 1